MorphoSys(MOR) - 2023 Q2 - Earnings Call Presentation

Q2 / H1 2023 Forward-Looking Statements Agenda 04 Q&A Jean-Paul Kress, Tim Demuth, Lucinda Crabtree Strategic Oncology Focus Supported by Strong Financial Position Drive use in second-line DLBCL, and expand into first-line setting Monjuvi® (tafasitamab-cxix) is only approved under accelerated approval by the U.S. FDA in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not ...